Standardization of methotrexate administration in routine rheumatological practice


Cite item

Full Text

Abstract

The review is devoted to administration of methotrexate - a basic anti-inflammatory drug - in rheumatoid arthritis. Some issues of practical use of this drug are still disputable. Recommendations of international experts and information on standardization for patients are considered.

About the authors

Yuriy Vladimirovich Murav'ev

Email: murawyu@mail.ru

Yu V Muravyev

Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow

Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow

References

  1. Gubner R. S., August V. R. Therapeutic suppression of tussue reactivity to effective aminopterin in rheumatoid arthritis and psoriasis. Am. J. Med. Sci. 1950; 220: 176-183.
  2. Weinblatt M. E., Coblyn J. S., Fox D. A. et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 1983; 312: 818-822.
  3. Williams H. J., Willkens R. F., Samuelson C. O. Jr. et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthr. and Rheum. 1985; 28: 721-730.
  4. Paulus H. E. FDA Arthritis Advisory Committee meeting: methotrexate; guidelines for the clinical evaluation of antiinflammatory drugs; DMSO in scleroderma. Arthr. and Rheum. 1986; 29: 1289-1290.
  5. Combe B., Landewe R., Lukas C. et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 2007; 66: 34-45.
  6. Tugwell P., Bennett K., Gent M. Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety. Ann. Intern. Med. 1987; 107: 358-366.
  7. Felson D., Anderson J. J., Meenan R. F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthr. and Rheum. 1990; 33: 1449-1461.
  8. Felson D., Anderson J. J., Meenan R. F. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthr. and Rheum. 1992; 35: 1117-1125.
  9. van der Heijde D., Burmester G., Melo-Gomes J. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. Ann. Rheum. Dis. 2008; 67: 182-188.
  10. Breedveld F. C., Weisman M. H., Kavanaugh A. F. et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthr. and Rheum. 2006; 54: 26-37.
  11. Heiberg M. S., Ródevand E., Mikkelsen K. et al. Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study. Ann. Rheum. Dis. 2006; 65: 1379-1383.
  12. Cohen S. B., Emery P., Greenwald M. W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthr. and Rheum. 2006; 54: 2793-2806.
  13. Emery P., Fleischmann R., Filipowicz-Sosnowska A. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthr. and Rheum. 2006; 54: 1390-1400.
  14. Kay J., Westhovens R. Methotrexate: the gold standard without standardization. Ann. Rheum. Dis. 2009; 68: 1081-1082.
  15. Visser K., Katchamart W., Loza E. et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann. Rheum. Dis. 2009; 68: 1086-1093.
  16. Roddy E., Zhang W., Doherty M. et al. Evidence-based clinical guidelines: a new system to better determine true strength of recommendation. J. Eval. Clin. Pract. 2006; 12: 347-352.
  17. Katchamart W., Bourré-Tessier J., Donka T. et al. Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. J. Rheumatol. 2010; 37: 1422-1430.
  18. Verstappen S. M., Hyrich K. L. Methotrexate for rheumatoid arthritis: a guide from Can. Rheumatol. 2010; 37: 1374-1376.
  19. Bogas M., Machado P., Mourao A. F. et al. Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review. Clin. Rheumatol. 2010; 29: 629-635.
  20. Borchers A. T., Keen C. L., Cheema G. S., Gershwin M. E. The use of methotrexate in rheumatoid arthritis. Semin. Arthr. and Rheum. 2004; 34: 465-483.
  21. Saleem B., Nizam S., Emery P. Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin. Exp. Rheumatol. 2006; 24 (6, Suppl. 43): 33-63.
  22. Mierau M., Schoels M., Gonda G. et al. Assessing remission im clinical practice. Rheumatology (Oxford) 2007; 46: 975-979.
  23. Luis M., Pacheco-Tena C., Cazarin-Barrientos J. et al. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study. Arthr. and Rheum. 1999; 42: 2160- 2165.
  24. Koivuniemi R., Leirisalo-Repo M., Suomalainen R. et al. Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand. J. Rheumatol. 2006; 35: 273-276.
  25. van der Veen M. J., van der Heide A., Kruize A. A., Bijlsma J. W. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann. Rheum. Dis. 1994; 53: 224-228.
  26. Furst D. E., Erikson N., Clute L. et al. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. J. Rheumatol. 1990; 17: 1628-1635.
  27. Schnabel A., Herlyn K., Burchardi C. et al. Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatol. Int. 1996; 15: 195-200.
  28. Wolfe F., Caplan L., Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthr. and Rheum. 2006; 54: 628-634.
  29. Antonelli M. A., Moreland L. W., Brick J. E. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am. J. Med. 1991; 90: 295-928.
  30. Mok M. Y., Ng W. L., Yuen M. F. et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin. Exp. Rheumatol. 2000; 18: 363-368.
  31. Nissen M. J., Fontanges E., Allam Y. et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford) 2005; 44: 1016-1020.
  32. Kujawska A., Clements M., Wise C. M., Roberts W. N. Hepatitis C and methotrexate. Arthr. and Rheum. 2003; 49: 843- 845.
  33. Iikuni N., Kitahama M., Ohta S. et al. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod. Rheumatol. 2006; 16: 282-288.
  34. Perhala R. S., Wilke W. S., Clough J. D., Segal A. M. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthr. and Rheum. 1991; 34: 146-152.
  35. Jain A., Witbreuk M., Ball C., Nanchahal J. Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J. Hand Surg. Am. 2002; 27: 449-455.
  36. Blóndal K. Barriers to reaching the targets for tuberculosis control: multidrug-resistant tuberculosis. Bull. Wld Hlth Org. 2007; 85: 387-390.
  37. Vadillo Font C., Hernández-Garcia C., Pato E. et al. Incidence and characteristics of tuberculosis in patients with autoimmune rheumatic diseases. Rev. Clin. Esp. 2003; 203: 178-182.
  38. McLean-Tooke A., Aldridge C., Waugh S. et al. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence? Rheumatology (Oxford) 2009; 48: 867-871.
  39. Thompson A. E., Bashook P. G. Rheumatologists' recommended patient information when prescribing methotrexate for rheumatoid arthritis. Clin. Exp. Rheumatol. 2010; 28: 539- 545.
  40. Buchbinder R., Hall S., Grant G. et al. Readability and content of supplementary written drug information for patients used by Australian rheumatologists. Med. J. Aust. 2001; 174: 575-578.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies